Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO), a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HbA1c), weight loss, blood pressure reduction and improvements in beta-cell functioning.

Participants in the study were randomized to receive liraglutide (1.8 mg or 1.2 mg dose) or placebo for 26 weeks in addition to metformin and rosiglitazone. Treatment with liraglutide in addition to metformin and rosiglitazone resulted in a mean reduction of 1.5% from baseline HbA1c. Fasting blood glucose levels decreased by 2.4 mmol/L within two weeks on 1.8 mg of liraglutide. More than half of the patients who received liraglutide reached the American Diabetes Association HbA1c target of <7.0% compared to 28% of those who received placebo. Likewise, more than 35% of the patients in the liraglutide groups reached HbA1c < or = 6.5% compared to 14% in the placebo group. In both cases, the difference between the groups receiving liraglutide and the group treated with metformin and rosiglitazone alone was statistically significant.

In addition to improved glucose lowering, liraglutide treatment also led to significant weight loss. Mean body weight decreased significantly for liraglutide compared to an increase in weight of 0.6 kg in the metformin and rosiglitazone only group. Weight is a common problem among individuals with type 2 diabetes and is one of the most challenging aspects in managing this condition.
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... MADISON, Wis., Aug. 8, 2011 Symphony Corporation, ... the acquisition of JGI, a New Jersey-based Human ... significant presence in the healthcare industry nationally.  Symphony,s ... its offerings to provide the highest level of ...
... DIEGO, Aug. 8, 2011 HUYA Bioscience International, a ... strategic partnership with the Shanghai Jiao Tong University School ... assist King,s Lab in accelerating the development of their ... provides HUYA with access to and first review of ...
Cached Medicine Technology:Symphony Corporation Acquires JGI to Provide End-to-End Services for Healthcare IT 2HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 2HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 3
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 “After my mom’s ... then had a stroke and loss the use of his left ... to design a way to help people like them enjoy eating ... created a prototype for the PATRICIA CAROL HALL PLATE (P C ... PLATE) offers a more ergonomic way to eat for individuals who ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... continue to move forward in U.S. courts, Bernstein Liebhard ... ties elevated metal ion levels to the failure of ... July 2nd issue of The Journal of Bone & ... had received unilateral Articular Surface Replacement prostheses at least ...
(Date:7/12/2014)... 12, 2014 For those who are unfamiliar ... readily absorb the nutrients in food. The enzymes literally break ... small enough to be absorbed by human bodies. According Dr. ... of enzymes in regular food is the cause of many ... was started by Michelle DelPresto, a mother of 3 who ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As reported in ... Institute of Standards and Technology), the June 25th, 2014 Supreme ... electronic discovery world. It was also met with ... depending on whether it was seen from an individual privacy ... much is fact, there is now precedent which will require ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5
... you could not find the price for anything at the ... check-out clerk offered to mail you a bill, but could ... Although that sounds ridiculous, that is exactly how our nation,s ... care reform debate charges forward, the unsustainable rise in health ...
... involved with the chemopreventative effect of aspirin on colorectal adenomas, ... the Journal of the National Cancer Institute . ... polyps, but it,s not clear how it works. One hypothesis ... as C-reactive protein and others, that are markers of inflammation. ...
... might yield insights into diseases like Parkinson,s, experts say , ... genetic mutation seem to be "smarter," in the sense of ... make correct decisions quickly, a new German study suggests. , ... the prefrontal cortex of the brain, activity that is probably ...
... Oct. 12 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) ... Chem www.slavicabiochem.com is providing an audio recording ... Filing service. The audio recording a wav file can ... transcript and the audio recording covers scientific topics and ...
... Iowa Committee for Value in Healthcare today issued a ... health care that Congress and the Obama administration should ... The committee found that Iowa, nationally recognized for high-value ... reform. Health care providers, purchasers, payers, patient advocates and ...
... Mourning, Kidney Care Partners Call Attention to Extended Medicare ... Access to Quality Care , WASHINGTON, Oct. 12 ... advocates, dialysis professionals, care providers and manufacturers working together ... disease and kidney failure - today applauded the Congressional ...
Cached Medicine News:Health News:Regence Video Asks 'What if Everything Worked Like Health Care?' 2Health News:Regence Video Asks 'What if Everything Worked Like Health Care?' 3Health News:Gene Mutation May Speed Learning 2Health News:Slavica Bio Chem (HTDS) Subsidiary Medical Team Message 2Health News:Slavica Bio Chem (HTDS) Subsidiary Medical Team Message 3Health News:Slavica Bio Chem (HTDS) Subsidiary Medical Team Message 4Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 2Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 3Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 4Health News:Iowa Committee Makes Recommendations to Increase Value in Health Care 5Health News:Kidney Care Community Commends Congressional Black Caucus for Naming Expansion of Medicare Provisions for Kidney Failure Patients as Top Priority 2Health News:Kidney Care Community Commends Congressional Black Caucus for Naming Expansion of Medicare Provisions for Kidney Failure Patients as Top Priority 3
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: